## Amendments to the Claims

1. (Currently amended) A method of treating an infection caused by herpesviridae or poxviridaevaccinia virus in a mammalian subject in need thereof comprising administering to said subject an effective amount of at least one compound according to the formula

$$R_1$$
 $R_3$ 
 $R_4$ 

wherein R<sub>1</sub> is selected from the group consisting of alkyl, aryl, O-aryl, S-aryl, OH, O-alkyl, SH, S-alkyl, NH<sub>2</sub>, N<sub>3</sub>, halogens, -OOCH, and COOH;

wherein R<sub>2</sub> is selected from the group consisting of H, hydroxyl, aliphatic and aromatic ethers and esters;

wherein R<sub>3</sub> is selected from the group consisting of alkyl, aryl, O-aryl, S-aryl, OH, O-alkyl, SH, S-alkyl, NH<sub>2</sub>, N<sub>3</sub>, halogens, -OOCH, COOH, siloxane rings, and acetal rings; and wherein R<sub>4</sub> is selected from the group consisting of alkyl, aryl, O-aryl, S-aryl, OH, O-alkyl, SH, S-alkyl, NH<sub>2</sub>, N<sub>3</sub>, halogens, -OOCH, COOH, siloxane rings, and acetal rings.

- 2. (Previously amended) A method as defined in claim 1, wherein  $R_1$  is phenyl;  $R_2$  is selected from the group consisting of -OMe, -OH, and -H;  $R_3$  is selected from the group consisting of -OH, -OAc, -OH, and -OBn; and  $R_4$  is selected from the group consisting of -H, -OAc, and -OBn; or a pharmaceutically active derivative thereof.
- 3. (Currently amended) A method as defined in claim 1, wherein the herpesviridae virus is human cytomegalovirus, wherein  $R_1$  and  $R_2$  form a ring comprising -OC(CH<sub>3</sub>)<sub>2</sub>O- and wherein  $R_3$  and  $R_4$  are each -OBn.

4.	(Currently amended) A method of treating an infection caused by human
cytome	egalovirus virus in a mammalian subject in need thereof comprising administering to said
subjec	t an effective amount of at least one compound as defined in claim 1, wherein R <sub>3</sub> and R <sub>4</sub>
form a	ring comprising a moiety preferably selected from the group consisting of -OSi(i-
Pr) <sub>2</sub> OS	$Si(i-Pr)_2O$ - and -OCH(Ph)O
5.	(Canceled)
6.	(Canceled)
7.	(Canceled)
8.	(Canceled)
9.	(Canceled)
10.	(Canceled)
11.	(Canceled)
12.	(Canceled)
	(Newly added) A method as defined in claim 4, wherein when $R_3$ and $R_4$ form a ring ising $-OSi(i-Pr)_2OSi(i-Pr)_2O-$ , $R_1$ is $-Ph$ , and $R_2$ is selected from the group consisting of d -OMe.
14.	(Newly added) A method as defined in claim 4, wherein when R <sub>3</sub> and R <sub>4</sub> form a ring ising -OCH(Ph)O-, R <sub>1</sub> is -Ph, and R <sub>2</sub> is -OMe.